SAVA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders
New York, New York--(Newsfile Corp. - September 14, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).
CLICK HERE FOR MORE DETAILS:
Affected shareholders purchased shares of SAVA between February 2, 2021 and August 24, 2021
Shareholders interested in representing the class of wronged shareholders have until October 26, 2021 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
According to a filed complaint, Cassava Sciences, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96594